Signal / reference entry
Retatrutide
Also listed as LY3437943
Start with the scope. Follow the sources. Use the reading note to examine how a claim is supported.
Reference fields
View sourcesApproval labels are specific to a product, route, and use. Read the scope and limitations together.
- Status for this entry
- Investigational
- Evidence label
- Randomized evidence
Status as of
- Product and use
- Investigational; no FDA-approved product.
- Route context
- Studied as a subcutaneous injection.
- Mechanism
- Activates GIP, GLP-1 and glucagon receptors.
- Evidence
- A randomized obesity trial was funded by Lilly.
- Limitations
- Trial averages do not predict an individual outcome.
- Safety
- The trial reported gastrointestinal adverse events.
Read beyond the claim
A closer reading
Try turning a headline into a question before opening the linked paper. Next, write down the question the paper says it was designed to answer. If the wording differs, identify the exact step needed to connect them. A broader headline might require an argument that the report itself never attempts; a narrower headline might leave relevant parts of the question unmentioned. Neither possibility should be assumed from the headline alone. The useful task is to make the proposed connection explicit, then decide whether the accompanying explanation actually supports that connection.
Questions to take to the source
- What question does the headline invite me to think was answered?
- How closely does that question match the purpose stated in the report?
- What additional reasoning would be needed to connect the two questions?
Filed under
- Metabolism
Topics organize the index; they do not describe a recommended use.
Sources
These references support the reference fields as a group. Follow each link to inspect its scope and wording.
- FDA GLP-1 FDA · Checked
- Jastreboff PubMed · Checked
Educational reference material. No clinician review is claimed. This entry does not provide personal medical advice.